Timely detection of novel coronavirus (2019-nCoV) infection cases is crucial to interrupt the spread of this virus. We assessed the required expertise and capacity for molecular detection of 2019-nCoV in specialised laboratories in 30 European Union/European Economic Area (EU/EEA) countries. Thirty-eight laboratories in 24 EU/EEA countries had diagnostic tests available by 29 January 2020. A coverage of all EU/EEA countries was expected by mid-February. Availability of primers/probes, positive controls and personnel were main implementation barriers.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029448 | PMC |
| http://dx.doi.org/10.2807/1560-7917.ES.2020.25.6.2000082 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tuberculosis in adult migrants in Europe: a TBnet consensus statement.
Eur Respir J
December 2024
Clinical Infectious Diseases, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.
Introduction: Global migration has increased in recent decades due to war, conflict, persecutions, and natural disasters, but also secondary to increased opportunities related to work or study. Migrants' risk of tuberculosis (TB) differs by reasons for migration, socioeconomic status, mode of travel and TB risk in transit, TB incidence and healthcare provision in country of origin. Despite advances in TB care for migrants and new treatment strategies, decisions for the management of migrants at risk of TB often rely on expert opinions, rather than clinical evidence.
View Article and Find Full Text PDFAntigenic changes in influenza A(H3N2) driven by genetic evolution: Insights from virological surveillance, EU/EEA, week 40/2023 to week 9/2024.
Euro Surveill
December 2024
Members of the ERLI-Net who contributed virus detection and/or characterisation data or were involved in weekly surveillance activities are listed under Collaborators (affiliations at the end of the article).
BackgroundDuring the 2023/24 influenza season in the European Union/European Economic Area (EU/EEA), influenza viruses A(H1N1)pdm09, A(H3N2) and B/Victoria viruses were co-circulating.AimWe aimed to describe the circulating influenza viruses by (sub)type, genetic clade, antigenic group and antiviral susceptibility in that season in the EU/EEA.MethodsWe collected surveillance data from EU/EEA countries through weekly submissions to The European Surveillance System (TESSy).
View Article and Find Full Text PDFTrends in new HIV diagnoses and factors contributing to late diagnosis among migrant populations in EU/EEA countries, 2014 to 2023.
Euro Surveill
November 2024
The members of the EU/EEA HIV network are listed under Collaborators.
Article Synopsis
- 45.9% of reported HIV cases were in migrants, with the majority (86.7%) coming from non-EU/EEA countries.
- A concerning 52.4% of migrants received a late HIV diagnosis, especially non-EU/EEA migrants through heterosexual transmission, highlighting the need for better prevention and testing strategies.
Differences in Patient Access to Newly Approved Antibacterial Drugs in EU/EEA Countries.
Antibiotics (Basel)
November 2024
Department of Health Technology Assessment, Faculty of Public Health, Medical University-Sofia, 1527 Sofia, Bulgaria.
Unlabelled: The introduction of antibiotics in the beginning of the 20th century was one of the most important scientific breakthroughs in history. However, in recent decades, the growing threat of antimicrobial resistance (AMR) has shown the limitations of the current research and development programs for new antimicrobial drugs. In the last decade, 20 antibiotics, 7 β-lactam/β-lactamase inhibitor (BL/BLI) combinations and 4 non-traditional antibacterial drugs have been launched worldwide.
View Article and Find Full Text PDFChildhood Mandatory Vaccinations: Current Situation in European Countries and Changes Occurred from 2014 to 2024.
Vaccines (Basel)
November 2024
Section of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
: Vaccination is one of the most effective public health interventions, preventing millions of deaths globally each year. However, vaccine hesitancy, driven by misinformation and reduced disease risk perception, has led to declining vaccination rates and the resurgence of vaccine-preventable diseases (VPDs) in Europe. In response to this, countries have implemented various strategies, including mandatory and recommended vaccination programs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!